Monthly Cost Breakdown: Budgeting Your Treatment Journey
What's Better Mounjaro or Wegovy: Understanding Monthly Cost Differences
When comparing what's better between Mounjaro and Wegovy for monthly budgeting, the cost structures differ significantly. Wegovy follows a structured 16-week escalation: 0.25mg costs £79.99 monthly, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), reaching £209.99 for the 2.4mg maintenance dose. Mounjaro has its own escalation schedule with different pricing points. Both are prescription-only medicines requiring clinical assessment through our GPhC-registered pharmacy #9012878.
The key difference lies in predictability versus mechanism of action. Wegovy's GLP-1-only approach provides straightforward monthly budgeting, whilst Mounjaro's dual GIP + GLP-1 mechanism offers different cost considerations. Neither treatment ensures specific outcomes, but both require long-term commitment alongside lifestyle changes. Your prescriber can help determine which monthly cost structure aligns with your financial planning and clinical needs.
Wegovy Pricing Structure: Complete Monthly Cost Analysis
EverydayMeds offers transparent Wegovy pricing with discount codes applied at checkout. New customers use code FIRST40, whilst returning customers apply DOSE25 to achieve these final prices. The 16-week escalation costs break down monthly: weeks 1-4 at £79.99, weeks 5-8 at £94.99, weeks 9-12 at £99.99, and weeks 13-16 at £139.99. From week 17 onwards, the maintenance dose costs £209.99 monthly.
Bundle options provide convenience for planning ahead. The Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99 for three months' supply, whilst the Ultimate Stability Trio offers three 2.4mg pens for £649.99. These bundles ensure treatment continuity without monthly reordering, though individual pen purchases remain flexible. Annual maintenance cost totals approximately £2,519.88 at the 2.4mg dose, helping with long-term budgeting decisions.
Clinical Evidence Behind What's Better Mounjaro or Wegovy Decisions
The STEP trial programme demonstrates Wegovy's clinical profile, with STEP 1 showing approximately 15% average weight loss at 68 weeks when used alongside diet and exercise (Wilding et al., NEJM, 2021). STEP 2 showed around clinically studied weight loss in patients with type 2 diabetes, whilst STEP 3 achieved approximately 16% with intensive behavioural therapy. These results inform clinical decision-making but don't predict individual outcomes.
Mounjaro's SURMOUNT trials showed different results due to its dual mechanism targeting both GIP and GLP-1 receptors. However, comparing trial percentages directly isn't meaningful due to different study designs, populations, and endpoints. Your prescriber considers multiple factors beyond cost when determining what's better between Mounjaro and Wegovy for your specific circumstances.
How Wegovy Works: Understanding Value for Monthly Investment
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones in your body. It works primarily by reducing appetite and promoting satiety after smaller meals, potentially reducing food cravings through effects on brain appetite centres. This mechanism operates continuously whilst the medication remains in your system, requiring weekly injections to maintain therapeutic levels. The monthly cost reflects this ongoing biological activity supporting weight management efforts. Unlike quick fixes, Wegovy requires sustained use alongside lifestyle modifications, making monthly budgeting essential for treatment success.
Ordering Process: From Assessment to Monthly Delivery
EverydayMeds streamlines the prescription process through a 3-minute online clinical assessment covering medical history, current medications, and treatment goals. Prescriber review typically takes 3 working days, with express 24-hour review available for urgent needs. Once approved, next-day delivery ensures temperature-controlled transport maintaining medication integrity. Monthly reordering becomes straightforward through your patient account, with automatic dose progression reminders during escalation phases. This systematic approach supports consistent treatment whilst managing monthly costs effectively through our GPhC-registered service #9012878.
Storage and Practical Considerations for Monthly Planning
Wegovy requires refrigerated storage between 2-8°C before first use, but offers practical advantages for travel and daily life. Once removed from the fridge, pens remain stable at room temperature below 30°C for up to 6 weeks, compared to Mounjaro's 21-day room temperature stability. The FlexTouch pen design enables straightforward weekly self-injection, whilst the structured dose escalation prevents tolerance development. Monthly prescription planning should account for storage space, travel requirements, and the mandatory escalation schedule that cannot be skipped or accelerated regardless of individual response.
Budgeting Strategies: What's Better Mounjaro or Wegovy for Long-term Affordability
When considering what's better between Mounjaro and Wegovy for monthly budgeting, factor in the total treatment duration and maintenance costs. Wegovy's maintenance phase represents the highest monthly expense at £209.99, continuing for as long as treatment remains beneficial. Weight regain studies show patients regained approximately two-thirds of lost weight within one year of stopping, emphasising long-term financial commitment.
Bundle purchasing can smooth monthly expense variations during escalation phases. The Progress Trio covers doses 0.5mg through 1.7mg for £369.99, spreading costs across three months. However, maintenance phase requires ongoing monthly investment without bundle savings, making this the primary budgeting consideration. Both treatments require similar long-term thinking, but Wegovy's established pricing structure aids financial planning.
Making Your Decision: Clinical and Financial Factors Combined
The question of what's better between Mounjaro and Wegovy extends beyond monthly costs to include clinical suitability, side effect profiles, and individual response patterns. Wegovy's GLP-1 mechanism suits patients responding well to appetite suppression, whilst Mounjaro's dual approach may benefit those needing additional metabolic effects. Monthly costs should align with treatment duration expectations and lifestyle budget constraints. Both medications are available from EverydayMeds, allowing prescriber choice based on clinical assessment rather than availability limitations. Your 3-minute assessment helps determine which option balances clinical needs with monthly affordability. Treatment success depends on consistent use alongside diet and exercise, making sustainable monthly budgeting crucial for long-term outcomes. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and receive personalised prescriber recommendations.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
